Elotuzumab-g2a/anti–PD-1 combination promotes infiltration and effector function of CD8⁺T cells. (A-E) A20-hSLAMF7–bearing mice were treated with control, 3 mg/kg anti–PD-1, 10 mg/kg elotuzumab-g2a, or elotuzumab-g2a plus anti–PD-1. Tumor-infiltrating and splenic CD8⁺ T cells were analyzed by flow cytometry (gated as live, GFP⁻CD19⁻CD3⁺CD8⁺). Quantification of (A) CD107a, (B) CD69, (C) PD-1, and (D) intracellular GrzB tumor-infiltrating and splenic CD8⁺ T cells as percentages of total CD8⁺ T cells isolated 10 to 14 days after the start of treatment. Results are a composite of 3 independent experiments with a total of 8 to 18 mice per group. (E) EG7-hSLAMF7–bearing mice were treated with control, 10 mg/kg elotuzumab-g2a, 10 mg/kg anti–PD-1, or elotuzumab-g2a plus anti–PD-1, injected intraperitoneally. Tumor-infiltrating and splenic OVA-tet⁺ CD8⁺ T cells were analyzed by flow cytometry (gated as live, GFP⁻CD19⁻CD3⁺CD8⁺OVA-tet⁺) and enumerated. Results are shown as mean ± SEM and are from a representative experiment with 7 to 8 mice per group. Statistical analyses were performed by using ANCOVA (A-D) and unpaired Student t test (E). *P < .05; **P < .01; ***P < .0001.